Althea

Based in Rome, Italy, Althea Group is an independent provider of integrated healthcare technology management and clinical engineering services for hospitals and clinics. The company generates its revenue through business-to-business service contracts that cover outsourced medical equipment maintenance, vendor-neutral procurement, and lifecycle management across various medical departments. Operating across more than fifteen countries, the organization currently manages over 1.4 million medical devices within approximately 2,700 public and private healthcare facilities. With a workforce of approximately 3,000 employees, the enterprise has attracted significant institutional investment from recognizable financial entities including Permira, F2i SGR, and Asterion Industrial Partners. In early 2023, a consortium led by F2i SGR and Asterion Industrial Partners officially completed their strategic acquisition of the company from its previous majority shareholders. Althea Group was originally established in 2014 by the global private equity firm Permira.

Althea is a name shared by multiple organizations; below I focus on the two most relevant technology/healthcare firms identifiable in public records (a healthcare-technology services group and a San Diego–based biologics contract development & manufacturing organization). If you meant a different “Althea,” tell me which one and I’ll adapt the profile.

High-Level Overview

• Althea Group (healthcare technology services): Althea is an integrated healthcare-technology management group that combines eight healthcare services companies to provide design, management and multivendor maintenance of medical devices and diagnostic imaging systems; it positions itself as an outsourced partner that takes technological and financial responsibility for customers’ clinical-technology assets to improve operational efficiency and reliability[1].
  - Althea Technologies (San Diego CDMO / biologics manufacturing): Althea Technologies is a contract development and manufacturing organization (CDMO) offering cGMP fill/finish, plasmid DNA and protein manufacturing, lyophilization, stability testing and related services for biotech and pharmaceutical clients; it expanded commercial biologics manufacturing capacity in San Diego and was acquired by Ajinomoto in 2013[2][4][3].
  

Origin Story

• Althea Group: The group describes itself as the result of combining eight leading healthcare services companies to deliver long-term technology management for healthcare providers; its public profile emphasizes expertise across biomedical equipment and diagnostic imaging and adherence to national and international quality standards, but public-facing pages do not list a single founding year or named partners on the profile page[1].
  - Althea Technologies (CDMO): Founded in 1998, Althea Technologies grew as a San Diego–based contract manufacturer focused on plasmid DNA, recombinant proteins and sterile drug-product filling; a key milestone was opening a commercial-scale GMP biologics manufacturing facility in Sorrento Valley (launched ~2009) and receiving FDA approval for commercial manufacturing after inspection in 2011; the company was acquired by Ajinomoto Co. in April 2013[2][4][3].

Core Differentiators

Althea Group (healthcare technology services)

• Integrated, multivendor technology management: offers design, management and multivendor maintenance across equipment types and manufacturers[1].
  - Independence from equipment manufacturers: positions itself as vendor‑agnostic to optimize device selection and lifecycle costs for customers[1].
  - End-to-end outsourcing model: takes both technological and financial responsibility, aligning its incentives with client efficiency and uptime[1].
  

Althea Technologies (CDMO)

• Full-service biologics and sterile fill/finish capabilities: supports plasmid DNA, recombinant proteins, lyophilization, vial/syringe sterile filling and stability testing under cGMP[2][4].
  - Commercial-scale GMP facility in a biotech hub: Sorrento Valley site with multiple GMP suites designed to scale from preclinical to commercial production[4].
  - Proven regulatory/inspection track record: facility completed a pre-approval inspection and gained FDA approval for commercial manufacturing operations[4].

Role in the Broader Tech / Healthcare Landscape

• Althea Group rides the wider trend toward outsourcing non-core clinical-technology operations and lifecycle management as healthcare providers aim to control costs, improve uptime and maintain compliance; vendor-agnostic technology management aligns with hospitals’ needs to manage multi-vendor fleets and complex imaging/diagnostic ecosystems[1].
  - Althea Technologies fits the growth of outsourced biomanufacturing and CDMO demand driven by increased biotech R&D, gene- and plasmid‑based therapeutics, and the need for flexible GMP capacity—especially in biotech clusters like San Diego where companies prefer local, scalable manufacturing partners[4][2].

Quick Take & Future Outlook

• For Althea Group: Continued healthcare cost pressures, rising device complexity (imaging, diagnostics) and tighter regulatory/compliance expectations make independent, integrated technology-management partners attractive; growth likely depends on scaling regional operator networks, demonstrating outcomes-based contracts, and deepening multivendor technical expertise[1].
  - For Althea Technologies (CDMO): Market demand for outsourced biologics and nucleic‑acid manufacturing (plasmid DNA, mRNA-enabling services) should support CDMOs with GMP capacity and regulatory experience; future value hinges on expanding cell/gene capabilities, capacity utilization, and strategic partnerships or M&A—consistent with its 2013 acquisition by Ajinomoto[4][2][3].
  

If you want, I can:

• Produce a single consolidated profile for one of these entities (specify which), or
  - Search for a different “Althea” (e.g., a startup or investment firm) if that’s the target you meant.